Interaction between Levothyroxine and Epinephrine
Moderate
Synergy
| ID | DDInter1064 and DDInter652 |
| Interaction |
The concomitant use of thyroid hormones, especially large doses, with sympathomimetic drugs may potentiate sympathomimetic effects and increase the risk of cardiac insufficiency in patients who have coronary artery disease.
abdominal distension
anaphylactic reaction
Anorexia
Anxiety
aortic regurgitation
Aphonia
Arthritis rheumatoid
atelectasis
atrioventricular block
blepharoptosis
More
|
| Management | Monitoring for increased sympathomimetic effects and cardiac function may be advisable. |
| References | |
| Alternative for Levothyroxine | - |
| Alternative for Epinephrine |
A01A
Triamcinolone (nasal)
Dexamethasone (ophthalmic)
Hydrocortisone (topical)
Dexamethasone (topical)
Amphotericin B (lipid complex)
Neomycin
Metronidazole (topical)
Amphotericin B (cholesteryl sulfate)
Tetracycline (topical)
Amphotericin B (liposomal)
Oxyquinoline (topical)
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.